Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

Antibodies against mutated citrullinated vimentin (AMCV) represent a useful diagnostic marker with correlation to disease activity in patients with rheumatoid arthritis (RA). Since seropositivity for citrullinated autoantibodies was predictive for response to B-cell depleting therapy (BCDT) with rituximab (RTX), we investigated whether differences in antibody fine reactivity and immunoglobulin (Ig) isotype kinetics among AMCV-positive patients could provide additional information about outcome. A total of 50 AMCV IgG-positive RA patients (RTX responders (RRs) n = 37 and non-responders (NRRs) n... Mehr ...

Verfasser: Lindenberg, Luisa
Dokumenttyp: Artikel
Reihe/Periodikum: Arthritis research & therapy
Verlag/Hrsg.: London, BioMed Central
Sprache: Englisch
ISSN: 1478-6354
Weitere Identifikatoren: doi: 10.1186/s13075-015-0717-z
Permalink: https://search.fid-benelux.de/Record/olc-benelux-1961018802
URL: NULL
NULL
Datenquelle: Online Contents Benelux; Originalkatalog
Powered By: Verbundzentrale des GBV (VZG)
Link(s) : http://dx.doi.org/10.1186/s13075-015-0717-z
http://dx.doi.org/10.1186/s13075-015-0717-z